Insider · CIK 0001975163

Kalofonos Isabel

Reports to the SEC for 3 companies · DALLAS, TX

sec.gov

Transactions

Companies

Filings

CIK

0001975163

Forms 4 and 5

Insider transactions

17 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-10-15	CGONCG Oncology, Inc. · Employee Stock Option (right to buy)A Award	Chief Commercial Officer	AAward	+92K sh	—	—	92,000
2026-09-01	CRNXCrinetics Pharmaceuticals, Inc.D Disposition to Issuer	Chief Commercial Officer	DDisposition to Issuer	−1,669 sh	$85.00	−$142K	34,000
2026-09-01	CRNXCrinetics Pharmaceuticals, Inc.D Disposition to Issuer	Chief Commercial Officer	DDisposition to Issuer	−34K sh	$85.00	−$2.89M	0
2026-09-01	CRNXCrinetics Pharmaceuticals, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Chief Commercial Officer	DDisposition to Issuer	−97.5K sh	$44.41	−$4.33M	0
2026-09-01	CRNXCrinetics Pharmaceuticals, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Chief Commercial Officer	DDisposition to Issuer	−55K sh	$41.21	−$2.27M	0
2026-02-23	CRNXCrinetics Pharmaceuticals, Inc.A Award	Chief Commercial Officer	AAward	+34K sh	—	—	34,834
2026-02-23	CRNXCrinetics Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Chief Commercial Officer	AAward	+55K sh	—	—	55,000
2026-01-05	CRNXCrinetics Pharmaceuticals, Inc.M Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	+2,500 sh	$40.59	+$101K	3,334
2026-01-05	CRNXCrinetics Pharmaceuticals, Inc.S Sale	Chief Commercial Officer	SSale	−2,500 sh	$55.00	−$138K	834
2026-01-05	CRNXCrinetics Pharmaceuticals, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	−2,500 sh	—	—	97,500
2025-01-10	CRNXCrinetics Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Chief Commercial Officer	AAward	+100K sh	—	—	100,000
2024-02-12	ImmunoGen, Inc.Stock Option (Right to Buy)D Disposition to Issuer	SVP & CHIEF COMMERCIAL OFFICER	DDisposition to Issuer	−284K sh	—	—	0
2024-02-12	ImmunoGen, Inc.Restricted Stock UnitD Disposition to Issuer	SVP & CHIEF COMMERCIAL OFFICER	DDisposition to Issuer	−47.4K sh	—	—	0
2024-02-12	ImmunoGen, Inc.Restricted Stock UnitD Disposition to Issuer	SVP & CHIEF COMMERCIAL OFFICER	DDisposition to Issuer	−19.5K sh	—	—	0
2024-02-01	ImmunoGen, Inc.Restricted Stock UnitA Award	SVP & CHIEF COMMERCIAL OFFICER	AAward	+19.5K sh	—	—	19,458
2023-04-28	ImmunoGen, Inc.Stock Option (Right to Buy)A Award	SVP & CHIEF COMMERCIAL OFFICER	AAward	+284K sh	—	—	284,250
2023-04-28	ImmunoGen, Inc.Restricted Stock UnitA Award	SVP & CHIEF COMMERCIAL OFFICER	AAward	+47.4K sh	—	—	47,375

Recent filings

Accepted (ET)
Oct 194
Kalofonos Isabel0001193125-26-425297
SEC(opens sec.gov)
Sep 14
Kalofonos Isabel0001628280-26-059885
SEC(opens sec.gov)
Feb 254
Kalofonos Isabel0001628280-26-011715
SEC(opens sec.gov)
Jan 74
Kalofonos Isabel0001628280-26-001230
SEC(opens sec.gov)
Jan 134
Kalofonos Isabel0000950170-25-004855
SEC(opens sec.gov)
Feb 124
Kalofonos Isabel0001104659-24-014700
SEC(opens sec.gov)
Feb 54
Kalofonos Isabel0001415889-24-002765
SEC(opens sec.gov)
May 24
Kalofonos Isabel0001415889-23-007094
SEC(opens sec.gov)

Companies

Address

C/O CG ONCOLOGY, INC. 3000 PEGASUS PARK DRIVE, SUITE 1640

DALLAS, TX, 75247